Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
Pharmaceutical Executive June 1, 2007 Jill Wechsler	Washington Report: Shop and Compare Insurers and payers believe that more comparative information on medical treatments will save money and improve care, but such analysis may be costly to pharma.
Pharmaceutical Executive October 1, 2008 Jill Wechsler	Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans.
The Motley Fool May 12, 2009 Brian Orelli	Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama.
BusinessWeek December 10, 2009 Weintraub & Wechsler	The New Prominence of Comparative Drug Trials Pharmaceutical makers, once wary of head-to-head trials, now embrace them as marketing tools.
The Motley Fool February 12, 2009 Brian Orelli	Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely.
Pharmaceutical Executive May 1, 2009 Jill Wechsler	Compared to What? Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
Pharmaceutical Executive February 1, 2006 Jill Wechsler	Washington Report: Cross-Agency Collaboration for Part D Medicare Part D gives CMS more clout over coverage, pricing, and even drug development.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
BusinessWeek June 9, 2009 John Carey	Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions
Pharmaceutical Executive October 1, 2008 Walter Armstrong	The Drug Vote '08 A head-to-head comparison of the Drug Vote '08
The Motley Fool June 19, 2009 Brian Orelli	Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies.
The Motley Fool November 30, 2009 Brian Orelli	The Real Problem With the Public Health-Care Plan The passing of a public plan probably won't affect the companies you invest in all that much, but there's certainly the possibility that a public plan could change into something that could do a lot more damage.
BusinessWeek November 12, 2009 Catherine Arnst	10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste.
The Motley Fool March 31, 2010 Brian Orelli	How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
Managed Care April 2004 John Carroll	$50M for Drug Comparisons Could Produce Valuable Results The Medicare amendment adopted late last year contains a provision that could help P&T committees, not to mention consumers, evaluate competing drugs.
Managed Care August 2007 Lola Butcher	Evidence-Based Medicine Is Not Enough Although EBM is only just getting started, many people are looking beyond evaluating treatments head to head and considering cost as well, although that raises political difficulties.
Pharmaceutical Executive July 1, 2012 Jill Wechsler	Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies.
The Motley Fool January 14, 2010 Jim Mueller	Roundtable: Which Health-Care Stocks to Buy Now Three Fool analysts give you their best ideas on where to put your money after the health-care reform bill makes it out of Congress.
Pharmaceutical Executive July 1, 2006 Jill Wechsler	Washington Report: Hard Evidence The push for more useful information on medication effectiveness is shaping drug development and reimbursement.
CFO Kris Frieswick	Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist...
The Motley Fool August 28, 2009	Roundtable: Will Health-Care Reform Kill Capitalism? Motley Fool analysts give their opinions on the health-care reform debate.
Pharmaceutical Executive February 1, 2009 Jill Wechsler	Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
Managed Care February 2007 Maggie Mahar	Why Market Competition Will Not Mend Our Health Care System Doctors have a saying: 'Half of what we know is wrong.' In which half is the conventional wisdom that competition is society's best hope for improving quality and controlling costs?
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
BusinessWeek October 1, 2009 Sasseen & Arnst	Why Business Fears the Public Option Executives contend that it will lead health-care providers to charge patients in private plans higher rates.
Pharmaceutical Executive June 1, 2005 Jill Wechsler	Washington Report: "D" Is for Data It is critical for Medicare to address important questions on drug safety and utilization, and about how prescribing decisions affect health outcomes and costs.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
BusinessWeek May 29, 2006 John Carey	When More Medicine Is Less A Dartmouth study finds a greater risk of death among patients treated in high-cost hospitals and clinics - and highlights conflicts of interest.
Pharmaceutical Executive November 1, 2013	Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.
CFO February 1, 2007 Karen M. Kroll	Pin the Tail on the Doctor A dearth of information leaves health-care consumers in the dark. As health-care information becomes more accessible, will employees use it to purchase health-care services more intelligently?
The Motley Fool September 20, 2007 Brian Orelli	Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress.
The Motley Fool April 22, 2009 Selena Maranjian	Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who.
BusinessWeek October 22, 2009 Sasseen & Arnst	Who Picks Up the Tab for Health Reform Insurers and taxpayers are likely to pay big chunks of the $900 billion bill to overhaul the nation's health-care system. Doctors will feel the least pain.
Knowledge@Wharton	Major Health Care Reform Under President Bush Remains Elusive Three of the chief health-care challenges facing the United States are: finding a way to provide coverage for the millions of uninsured, reforming Medicare, and setting up a prescription-drug plan for the elderly. The White House is likely to make headway on only the third of these in the next two years.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
The Motley Fool November 20, 2009 Kris Eddy	Drug Companies Targeted, Again Is a review of drug prices by Congress something to worry about?
BusinessWeek October 17, 2005 Amy Barrett	Prescription For Upheaval How the Medicare drug program is tightening the screws on Big Pharma.
The Motley Fool September 17, 2009 Brian Orelli	Baucuscare: Who's Paying? You are -- indirectly, of course. But nobody said reform would be cheap.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
BusinessWeek July 14, 2003 Howard Gleckman	This Medicare Reform Is No Cure The theory: The shift will improve treatment and save taxpayers money, helping to rein in ballooning Medicare costs while offsetting the expense of the drug benefit. Those are laudable goals. Unfortunately, Congress isn't likely to achieve them.
The Motley Fool October 30, 2009 Brian Orelli	Come On -- They Represent Your Mom! A Republican fight with AARP proves that we're still seeing politics as usual.
The Motley Fool July 31, 2009 Brian Orelli	A Health-Care Investor's Nightmare When it comes to health-care reform, no news is not good news; the House's recent plan to delay voting on a health-care reform bill until September should have investors reaching for the antacids.
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
BusinessWeek March 25, 2010 Charlie Rose	Aetna's Ron Williams on Health Care: What to Expect What does this new mandate mean for individuals, companies, and the health-care industry?
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
Pharmaceutical Executive September 1, 2011 Richard Gliklich	The Power of Observation Observational studies present a compelling real-world corollary to the classic randomized clinical trial.